The abstract is read at the publisher; the summary is JClub's.
Systemic butyrate or propionate administration in mouse cGVHD models mitigates disease and improves survival by reducing pathogenic hyperexpanded B cells and recipient-specific IgA.
- Why it matters: cGVHD drives major morbidity and mortality after allogeneic hematopoietic stem cell transplantation, and prior work linked low circulating SCFA to higher cGVHD incidence.
- What they did: The study tested butyrate and propionate in mouse models, then measured circulating B-cell expansion and antibody outputs, including recipient-specific IgA and total alloantibodies using rapid extracellular antigen profiling (REAP).
- The result: Exogenous SCFA treatment dampened antibody-dependent features of cGVHD, uncovering a microbiome-to-antibody mechanism that may inform other antibody-mediated pathologies.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.